Resources
These materials distinguish prior published work and university-originated intellectual property from the integrated development questions C1 Foundry still needs to answer.
Public record
Publications and patent records are linked directly. Company technical notes and presentations are labeled in preparation rather than represented as finished materials.
Peer-reviewed work relevant to the platform's synergistic substrate co-feeding foundation.
Park, J.O., Liu, N., Holinski, K.M. et al. Nature Metabolism 1, 643–651 (2019).
Reports controlled glucose and gluconate co-feeding in M. thermoacetica and Y. lipolytica to coordinate carbon, ATP, and reducing power.
View publication ↗Public university-originated patent records relevant to substrate co-feeding and engineered terpenoid production.
Inventors: Junyoung Park, Nian Liu, Gregory Stephanopoulos. Assignee: Massachusetts Institute of Technology.
Issued patent covering methods that use mixed substrate co-feeding for bioproduct synthesis.
View patent record ↗Inventors: Junyoung Park and Glenn Nurwono. The public record lists the University of California San Diego as assignee.
Pending application related to engineered production of bifunctional terpenoids.
View application record ↗Technical overviews and partner-facing platform materials.
In preparation
No public presentation is currently posted.
Focused notes on process architecture, product definition, and development metrics.
In preparation
Future notes will be added only when they are ready for public technical review.
C1 Foundry does not claim ownership of the university-originated records listed above. The company is pursuing the commercial rights necessary to practice and commercialize relevant university-originated intellectual property.
Evidence boundary
Prior work supports synergistic substrate co-feeding, C1-to-acetate conversion, and acetate-driven lipid synthesis. C1 Foundry's development work centers on integrating those elements with strain engineering and continuous bioprocessing while measuring productivity, titer, yield, composition, stability, energy demand, and recovery.
FAQ
The answers below separate the intended product and development objectives from claims the company is not making.
What does C1 Foundry intend to sell first?
The initial product is a lipid-rich SAF feedstock or intermediate for SAF producers and refiners. It would require downstream recovery, upgrading, qualification, and integration before becoming finished SAF.
Why use acetate as an intermediate?
Acetate creates a biological handoff between upstream C1 fixation and downstream lipid or hydrocarbon synthesis. That decoupling lets each process stage and organism be engineered around a more specific metabolic role.
What is established and what remains unresolved?
Published work supports the co-feeding concept and key conversion steps. Integrated continuous performance, useful volumetric productivity and titer, expanded hydrocarbon composition, process stability, and commercially relevant input and recovery requirements remain development questions.
Does C1 Foundry currently own the listed patents?
No ownership is claimed. The public records identify university assignees, and C1 Foundry is pursuing the commercial rights necessary to practice and commercialize relevant university-originated intellectual property.
Is the current material finished or ASTM-qualified SAF?
No. C1 Foundry is developing biological feedstocks and intermediates. Aviation-fuel upgrading, pathway qualification, blending decisions, and finished-fuel certification occur downstream.